MGMT and glioma: MGMT promoter methylation in high-grade astrocytomas and co-deletion of 1p/19q in oligodendrogliomas are proven prognostic and predictive markers that play a role in standard practice, and mutations of IDH1 or IDH2 are of strong prognostic value in lower grade gliomas (LGG), which are the most widely validated biomarkers in neuro-oncology currently [16, 17].